Shares of Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $2.33 and last traded at $1.78, with a volume of 224800 shares trading hands. The stock had previously closed at $1.75.
A number of equities analysts have recently weighed in on the company. Roth Capital reiterated a “buy” rating and set a $5.00 target price on shares of Aptose Biosciences in a research note on Monday, October 23rd. Zacks Investment Research upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Aptose Biosciences in a research note on Wednesday, December 13th. ValuEngine lowered Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, Canaccord Genuity set a $7.00 target price on Aptose Biosciences and gave the stock a “buy” rating in a research note on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $5.00.
The firm has a market capitalization of $41.73, a P/E ratio of -3.15 and a beta of 2.57.
TRADEMARK VIOLATION NOTICE: “Aptose Biosciences (APTO) Sets New 12-Month High at $2.33” was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://transcriptdaily.com/2017/12/28/aptose-biosciences-apto-sets-new-12-month-high-at-2-33.html.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.